The most common co-occurring alterations in CSF3R-mutated AML patients were DTA (DNMT3A, TET2 and ASXL1) mutations (9/13, 69.2%), splicing-factor mutations (4/13, 30.8%; 1 ZRSR2, 1 SF3B1, 2 SRSF2), RAS pathway mutations (3/13, 23.1%; 2 NRAS, 1 PTPN11), CEBPA (2/13, 15.4%), NPM1 (2/13,15.4%), and TP53 (2/13, 15.4%) (Fig. 3). This evidence concerns the gene TET2 and acute myeloid leukemia.